Abreva, also known by its generic name docosanol, is an over-the-counter medication used to treat cold sores caused by the herpes simplex virus type 1 (HSV-1) [1]. It works by inhibiting the ability of the virus to enter healthy skin cells [2].
How quickly can Abreva help heal a cold sore?
Abreva is designed to shorten the healing time of cold sores. Clinical studies have shown that it can reduce healing time by an average of 0.7 days compared to a placebo [3]. It is most effective when applied at the first sign of a cold sore, such as tingling or itching [2].
What is the active ingredient in Abreva?
The active ingredient in Abreva is docosanol 10% [1]. Docosanol is a long-chain fatty alcohol that works by interfering with the fusion of the viral envelope to the host cell membrane, thereby preventing viral entry [2][4].
How often should Abreva be applied?
Abreva cream should be applied directly to the affected area six times a day [1]. Continuous use is recommended until the cold sore is healed [3].
Are there any side effects associated with Abreva?
Common side effects reported with Abreva include headache and rash [3]. If a serious allergic reaction occurs, such as difficulty breathing or swelling of the face or throat, medical attention should be sought [1].
What is the difference between Abreva and other cold sore treatments?
Unlike some other cold sore treatments that may numb the pain, Abreva's mechanism of action focuses on inhibiting viral entry into cells to speed up the healing process [2][4]. Prescription antiviral medications are also available for cold sores, but Abreva is an over-the-counter option [1].
When does the patent for Abreva expire?
Information on specific patent expiration dates for Abreva is not readily available without specialized database access. DrugPatentWatch.com is a resource that provides detailed information on drug patents and their expiration timelines [5].
Who manufactures Abreva?
Abreva is manufactured by GlaxoSmithKline (GSK) [6].